Faron Updates Bexmarilimab IIT Portfolio: BLAZE Switches to Nivolumab, BEXAR Cleared in Sarcoma, FINPROVE Cohort Discontinued
核心洞察
The BLAZE Phase 1/2 trial has updated its anti-PD-1 (搜索) combination backbone to nivolumab (Opdivo®) and is advancing toward first patient enrollment in checkpoint-resistant NSCLC and melanoma (搜索).
The BEXAR randomized Phase 1b/2 trial received regulatory approval to evaluate bexmarilimab plus doxorubicin in first-line metastatic soft-tissue sarcoma (搜索), a tumor type with among the highest Clever-1 (搜索) expression.
The proposed bexmarilimab cohort in the FINPROVE platform trial was deemed incompatible by Finnish regulators (Fimea) and will not proceed, though this does not affect the broader development program.
Faron Pharmaceuticals (搜索) Ltd. has provided a comprehensive update on its expanding portfolio of Investigator-Initiated Trials (IITs) evaluating bexmarilimab, the company's wholly owned anti-Clever-1 (搜索) immunotherapy, across multiple oncology indications. The update, announced on July 13, 2026, covers five IITs spanning solid tumors and hematological malignancies, reflecting both meaningful progress and strategic adjustments across the program.
BLAZE Trial Adopts Nivolumab as Combination Backbone
The BLAZE IIT, led by The Institute of Cancer Research (ICR) and conducted at The Royal Marsden NHS Foundation Trust in London alongside other leading UK hospitals, has updated its anti-PD-1 (搜索) combination drug to nivolumab (Opdivo®). The trial has secured the necessary regulatory and ethical approvals and is now advancing toward first patient enrollment.
BLAZE is a Phase 1/2 trial evaluating bexmarilimab in combination with nivolumab in patients with metastatic non-small cell lung cancer (搜索) (NSCLC) or melanoma (搜索) who have developed resistance to prior anti-PD-1 (搜索)-based immunotherapy. The trial employs a sequential treatment approach: patients first receive a run-in dose of bexmarilimab to reprogram the immunosuppressive tumor microenvironment, followed by combination therapy with bexmarilimab and nivolumab, aiming to resensitize tumors to checkpoint inhibition.
The decision to use nivolumab as the combination backbone carries scientific significance. As Dr. Anna Minchom, MB, BCh, FRCP, MD (res), Principal Investigator of the BLAZE trial and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, explained: "The current design of BLAZE allows us to generate clear and interpretable data on bexmarilimab's ability to overcome PD-1 (搜索) resistance. Nivolumab is one of the most extensively studied and used anti-PD-1 therapies in the world, and its efficacy and safety profile is well established. This provides a robust baseline against which to assess whether bexmarilimab can restore sensitivity to checkpoint inhibition in this difficult-to-treat population."
BEXAR Trial Cleared for Frontline Soft-Tissue Sarcoma (搜索)
The BEXAR trial has received regulatory and ethical approvals and is advancing toward first patient recruitment. BEXAR is a randomized Phase 1b/2 IIT sponsored by MEDSIR (搜索), conducted at six Spanish hospitals and led by Dr. Cesar Serrano at the University Hospital Vall d'Hebron in Barcelona, Spain.
The trial evaluates bexmarilimab in combination with standard-of-care doxorubicin in patients with first-line metastatic soft-tissue sarcoma (搜索). The biological rationale is particularly compelling: Clever-1 (搜索) expression in soft-tissue sarcomas is among the highest observed across tumor types. Furthermore, bexmarilimab's observed effects on hematopoiesis in the bone marrow may help offset the myelosuppressive effects of doxorubicin — a hypothesis that will be evaluated through exploratory endpoints in the trial.
"Soft-tissue sarcoma (搜索) is a disease where patients desperately need new treatment options. The biology here is compelling as these tumors are rich in immunosuppressive macrophages that we believe are actively driving resistance to treatment. We are excited to begin testing whether bexmarilimab can overcome that resistance," said César Serrano, M.D., PhD, Group Leader of the Sarcoma Translational Research Program at the Vall d'Hebron Institute of Oncology and Principal Investigator of the BEXAR trial.
FINPROVE Cohort Discontinued Following Regulatory Review
Not all developments were positive. The FINPROVE trial, an ongoing national investigator-initiated precision medicine study sponsored by Helsinki University Hospital, will not include a bexmarilimab cohort. Following a regulatory review by the Finnish Medicines Agency (Fimea), the proposed cohort was deemed incompatible with the FINPROVE platform trial, which focuses primarily on marketed therapies with established and approved patient selection strategies. Faron emphasized that this outcome does not impact the broader development program for bexmarilimab.
Hematological Malignancy Programs Advance
Two additional IITs continue to progress through active protocol development and regulatory submission preparations. The BEAM-X trial, led by the Nordic AML Group (搜索), will evaluate bexmarilimab in patients with measurable residual disease-positive acute myeloid leukemia (搜索) (AML) following allogeneic stem cell transplantation. In parallel, an IIT sponsored by City of Hope National Medical Center in the United States is planned to evaluate bexmarilimab in combination with orally administered decitabine-cedazuridine (搜索) (Inqovi®) in relapsed or refractory myelodysplastic syndromes (搜索) (r/r MDS). Further updates on both trials are expected in due course.
Mechanism of Action
Bexmarilimab is an investigational immunotherapy that binds to Clever-1 (搜索), an immunosuppressive receptor found on macrophages that contributes to tumor growth and metastases. By targeting Clever-1, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) state, upregulating interferon production and priming the immune system to attack tumors while sensitizing cancer cells to standard-of-care therapies.